| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
23,124 |
21,510 |
$5.27M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,709 |
10,799 |
$676K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
11,886 |
11,010 |
$646K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
9,957 |
9,361 |
$600K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,644 |
1,476 |
$389K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,025 |
948 |
$277K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
360 |
338 |
$201K |
| 80053 |
Comprehensive metabolic panel |
11,406 |
9,474 |
$164K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,230 |
1,126 |
$119K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,130 |
2,707 |
$116K |
| 71045 |
Radiologic examination, chest; single view |
3,468 |
3,104 |
$105K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,269 |
9,173 |
$98K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
493 |
438 |
$75K |
| 87430 |
|
3,765 |
3,552 |
$65K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
468 |
340 |
$61K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
273 |
247 |
$59K |
| 84484 |
|
2,852 |
2,211 |
$36K |
| 83880 |
|
1,098 |
955 |
$34K |
| 81025 |
|
3,796 |
3,341 |
$32K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,766 |
3,212 |
$30K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
778 |
728 |
$27K |
| 87070 |
|
2,014 |
1,913 |
$26K |
| 71046 |
Radiologic examination, chest; 2 views |
643 |
606 |
$25K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
228 |
210 |
$24K |
| 87486 |
|
360 |
338 |
$21K |
| 76801 |
|
237 |
196 |
$20K |
| 87581 |
|
360 |
338 |
$20K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
360 |
338 |
$19K |
| 83690 |
|
2,773 |
2,411 |
$14K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,438 |
1,331 |
$13K |
| 81001 |
|
3,544 |
3,057 |
$12K |
| 36415 |
Collection of venous blood by venipuncture |
12,026 |
10,386 |
$12K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
78 |
66 |
$12K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
236 |
227 |
$11K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
355 |
298 |
$9K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
220 |
202 |
$9K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
220 |
202 |
$9K |
| 81003 |
|
2,903 |
2,564 |
$7K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
93 |
80 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
474 |
462 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
209 |
148 |
$7K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
146 |
136 |
$6K |
| 87420 |
|
160 |
150 |
$5K |
| 84702 |
|
569 |
451 |
$4K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,270 |
1,162 |
$4K |
| 87077 |
|
471 |
427 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
235 |
226 |
$4K |
| 85610 |
|
994 |
847 |
$3K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
21 |
12 |
$3K |
| 85730 |
|
675 |
598 |
$3K |
| 87186 |
|
436 |
354 |
$3K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
48 |
39 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,099 |
856 |
$2K |
| 85379 |
|
266 |
242 |
$2K |
| 83605 |
|
215 |
174 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
100 |
48 |
$2K |
| 84703 |
|
306 |
276 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
752 |
610 |
$2K |
| 86900 |
|
602 |
438 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,116 |
885 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,199 |
1,786 |
$2K |
| 85027 |
|
303 |
255 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
185 |
128 |
$1K |
| 86901 |
|
505 |
434 |
$1K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
871 |
743 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
71 |
64 |
$1K |
| 83735 |
|
146 |
94 |
$1K |
| 96376 |
|
198 |
109 |
$1K |
| 87210 |
|
173 |
156 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,640 |
2,134 |
$986.48 |
| 74018 |
|
13 |
12 |
$931.68 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
34 |
32 |
$878.61 |
| 93976 |
|
16 |
13 |
$732.41 |
| 73130 |
|
14 |
13 |
$710.92 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
898 |
744 |
$689.93 |
| 85007 |
|
203 |
169 |
$610.97 |
| 87081 |
|
117 |
116 |
$354.39 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
181 |
147 |
$344.55 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
325 |
266 |
$326.82 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
26 |
13 |
$191.61 |
| 87040 |
|
14 |
12 |
$156.24 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
153 |
136 |
$96.82 |
| 86850 |
|
13 |
13 |
$67.13 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
31 |
27 |
$24.13 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
173 |
135 |
$23.77 |
| 82962 |
|
1,067 |
584 |
$22.64 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
13 |
12 |
$3.45 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
2,378 |
1,726 |
$0.00 |
| 36592 |
|
20 |
16 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
128 |
106 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
27 |
23 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
18 |
14 |
$0.00 |